Bonnie Glisson
Medical Oncology · Houston, TXNPI 1073611950
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,205 of the $7,205 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Regeneron Healthcare Solutions, Inc..
Across 5 payments — averaging $1441.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$7K
Across 22 payments — averaging $25,143 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$418K
- Merck$101K
- AstraZeneca$30K
- AbbVie$5K
What the payments were for
- Consulting fees$7,205100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $7,205 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$7,205
How this compares
$7,205 in reported general payments places this provider in the 55th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.